Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.
cabazitaxel/Jevtana
cytochrome P450 3A (CYP3A4)
oral taxanes
pharmacokinetics
ritonavir
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
2
5
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
There is currently great interest in developing oral taxanes due to their lower costs and greater patient friendliness. We here wanted to test whether oral ritonavir, a cytochrome P450 3A (CYP3A) inhibitor, could boost the pharmacokinetics and tissue distribution of orally administered cabazitaxel (10 mg/kg) in male wild-type,
Identifiants
pubmed: 36976574
doi: 10.1021/acs.molpharmaceut.2c01076
doi:
Substances chimiques
Ritonavir
O3J8G9O825
Cytochrome P-450 CYP3A
EC 1.14.14.1
cabazitaxel
51F690397J
Taxoids
0
Enzyme Inhibitors
0
Cytochrome P-450 CYP3A Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM